PE-backed Caligor appoints new CFO/COO

Caligor, a portfolio company of Diversis Capital, has named Alex Shvartsburg as chief financial officer and chief operating officer. Previously, Shvartsburg worked at Thermo Fisher Scientific where he served as vice president of finance of the genetic, medical and applied sciences division. Secaucus, New Jersey and UK-based Caligor provides clinical trial supply and logistics services to the pharmaceutical and biotechnology sectors.


SECAUCUS, N.J.–(BUSINESS WIRE)–Caligor, a portfolio company of Diversis Capital, LLC, announced today that it has appointed Alex Shvartsburg as Chief Financial Officer and Chief Operating Officer. Mr. Shvartsburg brings more than 20 years of experience in the life sciences industry, serving in leadership roles with some of the world’s preeminent multinational organizations.

Most recently, Mr. Shvartsburg served as Vice President of Finance – Genetic, Medical and Applied Sciences Division (GSD) at Thermo Fisher Scientific, overseeing global financial operations for GSD. Before that, he was head of Life Technologies Corporate Development Finance Group, playing a key role in numerous M&A transactions, including a $15.8 billion acquisition of the company by Thermo Fisher Scientific. He began his career with Johnson and Johnson, progressing in roles of increasing responsibility. Mr. Shvartsburg’s experience with J&J includes domestic and international assignments, supporting Pharmaceutical, Medical Device and Consumer operating units.

“Alex has demonstrated significant leadership and expertise in high-growth organizations, and we are pleased to welcome him to the Caligor team,” said Tammy Bishop, Chief Executive Officer. “In addition to heading our financial strategy and operations, he will develop the analytics and help to set the strategic direction that will drive our decision-making as we continue to grow.”

“I am delighted to join Caligor, which through its outstanding client service, strategic insight and strong relationships has earned a reputation as the life sciences industry’s premier clinical trial sourcing company,” Mr. Shvartsburg said. “As a global specialist firm, Caligor is offering and developing the industry’s broadest set of strategic services, including accessing and distributing comparator drugs for clinical trial sponsors, managing named patient programs, overseeing the trial supply process and managing product life cycles. I look forward to contributing to Caligor’s international growth and operational success.”

Mr. Shvartsburg earned a Bachelor of Science degree in Accounting from Drexel University and a Master of Business Administration from LaSalle University. He is a Certified Management Accountant.

About Diversis Capital
Founded in 2013, Diversis Capital, LLC is a North American private equity firm with a focus on carve-outs, standalone deals and special situations in the lower and middle markets that require both sharp financial acumen and operational expertise to reach success. The tight-knit team of professionals has experience working on complex transactions and leveraging deep hands-on operational expertise to help companies and their management teams achieve full potential. Diversis, which was founded by Managing Directors Ron Nayot and Kevin Ma along with Marc Luzzatto, the firm’s Chairman, is currently in full acquisition mode with a goal of executing several transactions annually.

About Caligor
Caligor Opco LLC, a portfolio company of Diversis Capital, LLC, is a global company that manages the regulatory, logistics and supply chain challenges of sourcing, storing and distributing drugs for comparator clinical trials and expanded access programs. Through its proprietary TrialAssist™ program, Caligor optimizes comparator trials by providing value-added services including labeling, QP certification, storage, distribution and destruction of clinical trial products. We also are meeting the medical needs of patients worldwide by providing access to unlicensed medicines in situations where a drug has not yet been authorized in a patient’s home country, is in short supply or is otherwise commercially unavailable. The Company serves pharmaceutical and biotechnology companies from facilities in Secaucus, New Jersey and Dartford, UK, as well as depot locations worldwide. More information is available at